Olmesartan
Prescription ·Exploratory record · not publication-reviewed ·Updated July 13, 2026
Olmesartan is a potent ARB that provides effective blood pressure reduction with once-daily dosing. It is available in multiple fixed-dose combinations. Notably, it carries a unique FDA warning for sprue-like enteropathy, an adverse effect not typically seen with other ARBs.
Exploratory record, not a reviewed medical publication.
See the editorial and medical-review policies for the publication gate.
This generated database record has not completed a claim-level review by a qualified human medical reviewer. Bibliography links and evidence labels are not approval. The page remains available for reference and is excluded from search indexing.
What the research says.
A quick, data-only summary. The full evidence, dosing, and sources are below.
Olmesartan is a potent ARB that provides effective blood pressure reduction with once-daily dosing. NutriStack rates the supporting evidence as strong. Common adult dosing is 20–40 mg once daily (as prescribed by your physician), though a prescriber sets the actual dose. With long-term use it can deplete zinc. This profile indexes 10 sources.
The bottom line
Evidence rating strong. Most-documented uses: potent blood pressure reduction, effective once-daily dosing, available in combination with amlodipine and/or hctz. 10 sources indexed (2016–2024), with 0 interaction records on file.
How it works, mechanistically.
Core mechanism
Administered as the prodrug olmesartan medoxomil, which is rapidly hydrolyzed to the active olmesartan during absorption. Selectively blocks the AT1 receptor with high binding affinity. Prevents angiotensin II-mediated vasoconstriction, aldosterone release, and cardiac hypertrophy.3,1
Dosing & protocol.
Can be taken with or without food; prodrug rapidly converted to active form during absorption
What it depletes.
Nutrients this medication can lower over time, and what to replace.
Zinc
MildARB therapy can modestly increase urinary zinc losses in some users, though typically less than ACE inhibitors.
Full safety detail.
Sources, by evidence tier.
Numbered references. Citations throughout the page link here.
Meta-analyses & systematic reviews
5- 1Comparison of sacubitril/valsartan with olmesartan for hypertension: A meta-analysis of randomized controlled trialsPMIDSun Y, Yang H · Medicine · 2024
Sun Y, Yang H. Comparison of sacubitril/valsartan with olmesartan for hypertension: A meta-analysis of randomized controlled trials. Medicine. 2024
- 2Antihypertensive Effects of Sacubitril/Valsartan Versus Olmesartan: An Updated Systemic Review and Meta-Analysis of Randomized Controlled TrialsPMIDRaja R, Kumari S, Umer Khan M et al. · Cureus · 2023
Raja R, Kumari S, Umer Khan M et al.. Antihypertensive Effects of Sacubitril/Valsartan Versus Olmesartan: An Updated Systemic Review and Meta-Analysis of Randomized Controlled Trials. Cureus. 2023
- 3Exploring the Effectiveness and Safety of Azilsartan-Medoxomil/Chlorthalidone Versus Olmesartan-Medoxomil/Hydrochlorothiazide in Hypertensive Patients: A Meta-AnalysisPMIDKumar L, Khuwaja S, Kumar A et al. · Cureus · 2023
Kumar L, Khuwaja S, Kumar A et al.. Exploring the Effectiveness and Safety of Azilsartan-Medoxomil/Chlorthalidone Versus Olmesartan-Medoxomil/Hydrochlorothiazide in Hypertensive Patients: A Meta-Analysis. Cureus. 2023
- 4Efficacy and Safety Comparative of Sacubitril/Valsartan vs. Olmesartan in the Treatment of hypertension: A Meta-analysis of RCTsPMIDHan Y, Zhou Y, Na J et al. · American journal of hypertension · 2023
Han Y, Zhou Y, Na J et al.. Efficacy and Safety Comparative of Sacubitril/Valsartan vs. Olmesartan in the Treatment of hypertension: A Meta-analysis of RCTs. American journal of hypertension. 2023
- 5Olmesartan-associated sprue-like enteropathy: a systematic review with emphasis on histopathologyPMIDBurbure N, Lebwohl B, Arguelles-Grande C et al. · Human pathology · 2016
Burbure N, Lebwohl B, Arguelles-Grande C et al.. Olmesartan-associated sprue-like enteropathy: a systematic review with emphasis on histopathology. Human pathology. 2016
Reference material
5- 6Dahlof B et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE). Lancet. 2002.Source linkedPMID
- 7Granger CB et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors (CHARM-Alternative). Lancet. 2003.Source linkedPMID
- 8Qian J et al. A Systematic Literature Review and Network Meta-analysis of Azilsartan Medoxomil Compared to Other Anti-hypertensives Efficacy in Lowering Blood Pressure Amongst Mild to Moderate Hypertensive Patients. Adv Ther. 2024.Source linkedPMID
- 9Kario K, Rakugi H, Yarimizu D et al.. Twenty-Four-Hour Blood Pressure-Lowering Efficacy of Sacubitril/Valsartan Versus Olmesartan in Japanese Patients With Essential Hypertension Based on Nocturnal Blood Pressure Dipping Status: A Post Hoc Analysis of Data From a Randomized, Double-Blind Multicenter Study. Journal of the American Heart Association. 2023Source linkedPMID
- 10Rakugi H, Kario K, Yamaguchi M et al.. Efficacy of sacubitril/valsartan versus olmesartan in Japanese patients with essential hypertension: a randomized, double-blind, multicenter study. Hypertension research : official journal of the Japanese Society of Hypertension. 2022Source linkedPMID
Common questions.
Quick answers about Olmesartan, drawn from the data on this page.
What is Olmesartan?
Olmesartan is a potent ARB that provides effective blood pressure reduction with once-daily dosing. It is available in multiple fixed-dose combinations. Notably, it carries a unique FDA warning for sprue-like enteropathy, an adverse effect not typically seen with other ARBs.
What is Olmesartan used for?
Commonly cited benefits of Olmesartan include: Potent blood pressure reduction; Effective once-daily dosing; Available in combination with amlodipine and/or HCTZ; Consistent 24-hour blood pressure control. NutriStack rates the overall evidence as strong.
What is a typical dose of Olmesartan?
A typical adult dose of Olmesartan is 20–40 mg once daily (as prescribed by your physician). The commonly recommended form is Oral tablet. These are general ranges, not personalized advice; confirm the right dose with a clinician.
What are the side effects of Olmesartan?
Reported side effects include dizziness, hyperkalemia, diarrhea, sprue-like enteropathy (chronic diarrhea, weight loss, rare but important), upper respiratory tract infection, hypotension. This is educational information; check with a healthcare professional before use.
How strong is the evidence for Olmesartan?
NutriStack rates this as Strong, meaning multiple high-quality meta-analyses or systematic reviews converge on the same finding. Full tier criteria are at https://nutristackapp.com/methodology/evidence-tiers.
Use this with your stack
Olmesartan in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.